Paris—Dentons has advised H.A.C. Pharma, on the acquisition of the European and UK rights to the drug product TARGRETIN® (bexarotene) from Eisai Co., Ltd. This strategic acquisition marks a key milestone in HAC Pharma’s growth strategy in Europe, bolstering its portfolio in the therapeutic area of hematology and its commitment to advancing therapeutic innovation.

Philippe BISSAY, Chairman and CEO of H.A.C. Pharma, commented: “This second acquisition in 2024 rewards the intensive work of our teams and validates our development strategy in Europe, based on the acquisition of proven molecules and the launch of innovative products under license.”

A multidisciplinary team from Dentons’ Paris office provided H.A.C. Pharma with seamless legal and strategic guidance throughout the transaction. The team was led by Julien Le Guyader Partner and Co-Head of the Paris Life Sciences team) and included Guillaume Kessler (Partner, Corporate and M&A), Loïc Lemercier (Partner, Intellectual Property), Claire Picard (Counsel, Litigation and Dispute Resolution), Jessica Garestier (Counsel, Life Sciences), Caroline Pucel (Counsel, Corporate and M&A), David L. (Counsel, Tax), Steeve Jaskierowicz (Counsel, Banking and Finance), Tom Blanchet (Senior Associate, Intellectual Property), and  Chen Gu (Associate, Intellectual Property).

Julien Le Guyader, stated: “We are proud to have supported HAC Pharma in this strategic acquisition, which will enhance their capacity to provide innovative solutions in the hematology space. This project exemplifies the strength of Dentons’ multidisciplinary and collaborative approach, bringing together experts across practice areas to deliver exceptional results for our clients.”

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com